Spectral Med Inc (EDT.TO) is seeing a boost in its stock price, reflecting investor confidence and interest in the market.
In the latest trading session, Spectral Med Inc's stock rose by 1.49%, closing at CA$1.36. This increase comes as the company progresses with its clinical trials and regulatory preparations, hinting at a promising future for investors.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$393.18M
52W high
$1.76
52W low
$0.77
1W change
+0.00%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 135.1% over the next 12 months.
Consensus
No RatingAvg. Target
C$3.15
+135.1% Upside
Current Price
C$1.34
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
21.6%
Annualized
90-Day Vol
33.4%
Annualized
Trend (90d)
-15.4%
Annualized drift
90d Mean
C$1.27
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.32 | C$1.22 โ C$1.42 |
| 60 trading days | C$1.29 | C$1.16 โ C$1.44 |
| 90 trading days | C$1.27 | C$1.11 โ C$1.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: For Canadian investors, this recent gain in Spectral Med Inc's stock may indicate growing confidence in the company's future, especially as it makes strides in important clinical trials and regulatory processes.
Spectral Med Inc Stock Up 1.49% in One Day
With a market cap of CA$393.18 million, Spectral Med's recent stock performance shows increasing interest in its innovative medical solutions.
Bull case
The rise in Spectral Med's stock could be due to investor optimism about its Tigris trial and the potential FDA approval for its PMX product, which could lead to significant market opportunities.
Bear case
On the flip side, investors should stay cautious since the company has not yet turned a profit or paid dividends, and any delays in regulatory approvals could affect stock performance.
Recent Performance Overview
Spectral Med Inc's stock has increased by 1.49% in the last trading session, closing at CA$1.36. This rise is noteworthy given the company's market cap of CA$393.18 million, showing a healthy level of investor interest.
Factors Driving Investor Confidence
The recent gains are fueled by positive sentiment around the company's advancements in clinical trials, especially the Tigris trial. Investors are closely watching for updates on regulatory approvals that could greatly influence the company's future.
Looking Ahead
As Spectral Med Inc moves forward with its clinical trials and regulatory processes, investors should keep an eye on upcoming milestones. The company's ability to navigate these challenges will be key to maintaining its stock performance in the future. For more detailed insights, visit our Spectral Med Inc stock page.
Advertisement
